Category - Developments

Developments

Clearmind granted patent for binge behavior treatment in Macau

Clearmind Medicine (NASDAQ:CMND; FSE:CWY0) has announced that its proprietary MEAI-based binge behavior regulator program has received patent approval from the Macau International Intellectual Property Office, a special...

January 3, 2025

Developments

Eton acquires rare disease product Galzin

Eton Pharmaceuticals (NASDAQ:ETON) has announced the acquisition of Galzin, a rare disease product used in the treatment of Wilson disease. The company reports that Galzin, an FDA-approved zinc acetate, is utilized as a...

January 3, 2025

Developments

Japan approves SIGA’s antiviral for orthopoxvirus

SIGA Technologies (NASDAQ:SIGA) has announced that its product, TEPOXX, an antiviral therapy targeting orthopoxviruses, has received approval from Japan’s Pharmaceuticals and Medical Devices Agency and the Japan...

January 3, 2025

Developments

Oruka initiates dosing of first patient in Phase 1 trial of ORKA-001

Oruka Therapeutics (NASDAQ:ORKA) has announced the initiation of dosing of in its Phase 1 clinical trial of ORKA-001, a subcutaneously administered, half-life extended monoclonal antibody targeting IL-23p19. Inhibitors...

December 20, 2024

Developments

FDA approval of Mesoblast’s RYONCIL bodes well for other cell therapy companies like BioRestorative Therapies and Cell Technologies

Mesoblast (ASX:MSB; NASDAQ:MESO) is rallying today after the company announced yesterday after market close that the FDA approved RYONCIL (remestemcel-L), an allogeneic (donor) bone marrow-derived mesenchymal stromal...

December 19, 2024

Developments

Silo initiates PK and tolerability study for non-opioid extended-release pain therapeutic

Silo Pharma (NASDAQ:SILO) has announced the initiation of a preclinical pharmacokinetic (PK) and tolerability study, in partnership with AmplifyBio, to assess Silo’s dissolvable, ketamine-based injectable implant, SP-26...

December 18, 2024

Developments

Larimar reports positive initial data from OLE study of nomlabofusp in FA

Larimar Therapeutics (NASDAQ:LRMR) has announced positive initial results from its ongoing open-label extension (OLE) study evaluating daily subcutaneous injections of 25 mg of nomlabofusp, either self-administered or...

December 16, 2024

Developments

MindMed announces first patient dosed in Phase 3 study of LSD in GAD

MindMed (NASDAQ:MNMD) has announced that the first patient has been dosed in its Phase 3 Voyage study of MM120, an orally disintegrating tablet (ODT) and pharmaceutically optimized form of LSD, in generalized anxiety...

December 16, 2024

Developments

Fractyl reveals promising preclinical data for pancreatic gene therapy program

Fractyl Health (NASDAQ:GUTS) has announced that it will present new data from its RJVA-001 Rejuva Smart GLP-1 pancreatic gene therapy program for the treatment of obesity and type 2 diabetes (T2D) at the 22nd World...

December 12, 2024

Developments

Candel achieves primary endpoint in Phase 3 trial evaluating CAN-2409 in prostate cancer

Candel Therapeutics (NASDAQ:CADL) has announced results from its multicenter Phase 3 trial evaluating CAN-2409 viral immunotherapy in patients with localized prostate cancer. The study achieved its primary endpoint...

December 11, 2024

Category - Developments

Subscribe